Mutant p53 reactivation by small molecules makes its way to the clinic.
about
Chemical Variations on the p53 Reactivation ThemeTargeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapyClinical Overview of MDM2/X-Targeted TherapiesMutant p53: One, No One, and One Hundred ThousandTargeting Oncogenic Mutant p53 for Cancer TherapyGenetic instability in the tumor microenvironment: a new look at an old neighborThe role of p53 in cancer drug resistance and targeted chemotherapyMutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and HypoxiaHomeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect.Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-moleculeSF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy.PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.Metabolic pathways regulated by TAp73 in response to oxidative stressOptimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo.Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulationClinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.TP53: an oncogene in disguise.The next steps in improving the outcomes of advanced ovarian cancer.Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells.Downregulation of cell cycle-related proteins in ovarian cancer line and cell cycle arrest induced by microRNA.The "Jekyll and Hyde" Actions of Nucleic Acids on the Prion-like Aggregation of Proteins.Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.Targeting mutant p53 in cancer: a long road to precision therapy.p53 Replacement Therapy for Cancer.Exploiting the p53 Pathway for Therapy.Using yeast to determine the functional consequences of mutations in the human p53 tumor suppressor gene: An introductory course-based undergraduate research experience in molecular and cell biology.Understanding cell cycle and cell death regulation provides novel weapons against human diseases.MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact.MicroRNA-200c is involved in proliferation of gastric cancer by directly repressing p27Kip1.The dominant-negative interplay between p53, p63 and p73: A family affair.Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.The rare nonsense mutation in p53 triggers alternative splicing to produce a protein capable of inducing apoptosis.
P2860
Q26749008-B169FA80-E116-4C42-A632-4DDF149292BEQ26766341-31ADCB1D-C821-4B19-86E3-23D8DD69487CQ26767402-51D152C1-02C2-49A2-8818-48AC12671E62Q26770576-981B502A-6AD0-4095-A2E4-0F5601E71E6FQ26770856-0E45BDB2-3E24-412E-92D5-2D967AA24EE2Q26801374-C996F59E-61E7-49B6-8A64-DB42797B1E80Q28072553-09EBBE40-38C0-4B66-9F42-68C22E2453CEQ30354662-C61B37A5-22CC-4406-A4AB-BF87D92337F3Q33820876-C2CFC6C3-8F1E-4864-BA38-DC17FAA3BB0EQ35666395-1D14DA23-3774-40C5-87A6-57C34CA588E8Q35886639-2DB4480C-DF36-4BE0-B4C1-548E5168BF2AQ35925679-DA601658-9AFB-4AE0-B065-80A36476816FQ36334031-F366117E-9F3F-4854-87B4-7C54B192325AQ36546764-35FE9727-AD7C-482B-9C2C-52AFB0BC2086Q36905671-70563F80-97D1-4129-AF5E-DBEA1792B25EQ37247680-1B122661-8C0A-439F-A3FC-0CBD8C5BB5F0Q37327366-247981E9-5A0B-404D-B63D-2EE9347EE7E8Q37388203-3890BD7B-8D4B-4F57-B5F8-6DDE0936BCACQ37693722-902F1550-B314-40B5-A34C-526B2E1418F2Q37718416-BEAE7252-F758-493B-A44B-197CF6536D65Q37736385-30BC7ECA-D406-4FEF-8CD4-8546A4ABBD4CQ38380481-21E0CB48-9374-45D5-A529-C1C206328867Q38507513-8E693E3A-5EF3-40A8-9BD7-5602DFF9C9B8Q38535374-0D4A06FF-E367-47B4-90BB-F79E34112214Q38633437-855323ED-334F-41A0-97E8-FEDAB946006AQ38697712-6ECE675F-6F39-4079-88AC-6640010F8AEFQ38803380-2FA4FF1D-AE90-445D-ABA3-3A513F77ABE5Q38861978-DC3A7533-E899-475F-B12D-3B2D80A3385FQ38934098-4ED556CF-D06E-485B-9179-4432BF888121Q38948352-0CE6714B-B293-4C0C-B358-B6058A385C82Q38997351-24CDFDA1-869F-44F4-A6C6-A1DF45D0AE6BQ39094425-7572AA65-DBF5-4A97-83FD-7D2EB10F4049Q39134087-E8B53FC7-CCB6-4C04-9CD4-23A1164F7C50Q39165408-830930B6-801B-46A5-B115-B264258E2606Q39218376-DC378FED-0723-4A5B-A763-00CD7439E63BQ39433270-E064673F-6431-4C2C-850A-FE25AA78672CQ41682632-869606E3-320B-4C1D-9517-05346F520EB8Q42134524-47D48B08-2375-430D-AE7F-C7D59C80B0BEQ42367187-B34E9783-BA71-4F68-8076-9F1DFDDB18CFQ42367544-047BA4FD-B9BA-450B-B2C7-83A89BBFFEE5
P2860
Mutant p53 reactivation by small molecules makes its way to the clinic.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mutant p53 reactivation by small molecules makes its way to the clinic.
@ast
Mutant p53 reactivation by small molecules makes its way to the clinic.
@en
type
label
Mutant p53 reactivation by small molecules makes its way to the clinic.
@ast
Mutant p53 reactivation by small molecules makes its way to the clinic.
@en
prefLabel
Mutant p53 reactivation by small molecules makes its way to the clinic.
@ast
Mutant p53 reactivation by small molecules makes its way to the clinic.
@en
P1433
P1476
Mutant p53 reactivation by small molecules makes its way to the clinic
@en
P2093
Vladimir J N Bykov
P304
P356
10.1016/J.FEBSLET.2014.04.017
P407
P50
P577
2014-04-24T00:00:00Z